In addition to tapering CNIs, our group has studied the effects of mammalian target of rapamycin (mTOR) antagonists on the incidence of post-transplant malignancies including PTLD among HT recipients (42). The gene discussed is MTOR; the disease is post-transplant lymphoproliferative disease.